Roxanol

A case of fatal intoxication of an 8 year old child due to accidental oral ingestion of morphine is presented. Following a tonsillectomy and release from the hospital the decedent was prescribed meperidine syrup 50 mg per teaspoon (tsp) to be taken 2 tsps every 4 h. A pharmacist when filling her prescription mistakenly dispensed Roxanol which contained 20 mg/ml morphine sulfate. She took 1 or 2 tsp of the prescription prior to bed and was found dead the next morning. Autopsy findings were unremarkable. Quantitation by gas chromatography/mass spectrometry (GC/MS) yielded the following morphine results: blood, 0...

PURPOSE: This study was conducted to compare the relative analgesic efficacy and safety of an every-4-hour immediate-release oral morphine (IRM) solution with that of an every-12-hour sustained-release oral morphine (SRM) formulation. PATIENTS AND METHODS: This was a double-blind, placebo-blinded, crossover study in 34 adult male and female outpatients with pain due to advanced cancer. Baseline data were collected on day 1. On days 2 and 3, randomly assigned patients received either placebo plus IRM (Roxanol; Roxane Laboratories, Inc, Columbus, OH; 20 mg/mL) at 2, 6, and 10 am, and 2, 6, and 10 pm, or alternatively SRM (Oramorph SR; Roxane Laboratories, Inc; 30 mg) at 10 AM and 10 PM...

OBJECTIVE: Patients with terminal cancer often receive continuous enteral nutrition and oral medications concomitantly through nasogastric or gastrostomy feeding tubes. This study evaluated in vitro the compatibility of morphine sulfate (MS) solution 2 mg/mL (Roxane Laboratories) with three enteral nutrition products (Jevity [J], Osmolite-HN [O], and Pulmocare [P]) at 22 and 37 degrees C for 48 hours and J alone at 50 degrees C for 48 hours. METHODS: Mixtures containing 1 mg/mL MS were prepared with each enteral product: J, O, and P (Ross Laboratories)...

Thirty-seven patients with advanced cancer requiring oral administration of strong narcotics for pain control have been treated with one or other of two commercially-available, sustained-release morphine preparations. Patients were followed up primarily at home, supervised by a local hospice care team, and received daily dosage ranging from 60 mg to 420 mg morphine administered as 30 mg sustained-release tablets delivered at intervals from 6 to 10 hours for 'Roxanol SR' and from 8 to 14 hours for 'MS Contin'...

The pharmacokinetic profiles of two oral controlled-release morphine formulations, MS Contin tablets and Roxanol SR tablets, were compared to evaluate their bioequivalence. In a sequential, crossover study, 18 healthy young male volunteers received single 60-mg doses (two 30-mg tablets) of each formulation and provided 15 serial blood samples over 24 hours, which were assayed to determine their morphine concentrations by high-performance liquid chromatography. Analysis of variance revealed significant differences between the treatments for maximum plasma concentration (P less than 0...